Janney Montgomery Scott Upgrades BioDelivery Sciences International (BDSI) to Buy

September 23, 2016 7:25 AM EDT
Get Alerts BDSI Hot Sheet
Price: $2.00 --0%

Rating Summary:
    7 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade BDSI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Janney Montgomery Scott upgraded BioDelivery Sciences International (NASDAQ: BDSI) from Neutral to Buy with a price target of $4.00 as Belbuca will be added as the preferred brand over Butrant on United Healthcare Formulary.

Analyst Ken Trbovich commented, "Endo International plc (NASDAQ: ENDP) has not yet announced, but clearly won preferred status for Belbuca relative to market leader Butrans on the Prescription Drug List at United Healthcare. ENDP's initial launch has been disappointing, but the United contract improves the outlook and is set to take effect on January 1, 2017. Additionally, BDSI has announced five contract wins for Bunavail since July. This places BDSI on a path to show meaningful growth for Bunavail growth in 2017. As a result, our preliminary 2017 BDSI revenue estimate of $25 mln shows significant improvement from our current 2016 estimate of $15 mln. Based on the improved outlook we are raising our rating to Buy and maintaining our $4 fair value estimate."

For an analyst ratings summary and ratings history on BioDelivery Sciences International click here. For more ratings news on BioDelivery Sciences International click here.

Shares of BioDelivery Sciences International closed at $2.45 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Upgrades, Upgrades

Related Entities

Janney Montgomery Scott

Add Your Comment